Skip to main navigation

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact

News Releases

News Releases

Year

Sep 22, 2023

Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference

Sep 15, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 07, 2023

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

Aug 22, 2023

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

Aug 11, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 03, 2023

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

Aug 03, 2023

Fulcrum Therapeutics Appoints Chief Financial Officer

Jul 27, 2023

Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET

Jul 10, 2023

Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

Jul 07, 2023

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 29

Investor Tools

Code of Conduct & Business Ethics

Privacy Policy | EU Privacy Policy | Terms of use

Social Media Guidelines

Main Menu

About
Our Approach
Pipeline
- Publications
Therapeutic Focus
Careers
- Current Openings
- Faces of Fulcrum
Investor Relations
Contact